Drug Addiction - Pipeline Review, H2 2017

Published: Jul, 2017 | Pages: 162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Drug Addiction - Overview 7
Drug Addiction - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Drug Addiction - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Addiction - Companies Involved in Therapeutics Development 28
Addex Therapeutics Ltd 28
Aelis Farma SAS 28
Aphios Corp 29
BioCorRx Inc 29
Cerecor Inc 30
Chiesi Farmaceutici SpA 30
Curemark LLC 31
Egalet Corp 31
Embera NeuroTherapeutics Inc 32
F. Hoffmann-La Roche Ltd 32
Foresee Pharmaceuticals LLC 33
Heptares Therapeutics Ltd 33
Immunovaccine Inc 34
Indivior Plc 34
InterveXion Therapeutics LLC 35
Intra-Cellular Therapies Inc 35
Kyorin Pharmaceutical Co Ltd 36
Kyowa Hakko Kirin Co Ltd 36
Omeros Corp 37
Opiant Pharmaceuticals Inc 37
Orexigen Therapeutics Inc 38
P2D Bioscience 38
Saniona AB 39
Stada Arzneimittel AG 39
Teva Pharmaceutical Industries Ltd 40
Zynerba Pharmaceuticals Inc 40
Drug Addiction - Drug Profiles 41
(acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile 41
(hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile 42
(metyrapone + oxazepam) - Drug Profile 43
18-MC - Drug Profile 46
ADX-71441 - Drug Profile 48
ADX-71743 - Drug Profile 53
ADX-88178 - Drug Profile 54
AEF-0117 - Drug Profile 57
ANS-6637 - Drug Profile 58
AT-076 - Drug Profile 59
AT-089 - Drug Profile 60
AT-1001 - Drug Profile 61
AT-212 - Drug Profile 62
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile 63
cannabidiol - Drug Profile 64
CERC-501 - Drug Profile 65
CM-1212 - Drug Profile 68
DDD-024 - Drug Profile 69
dronabinol - Drug Profile 70
dronabinol - Drug Profile 71
Drug for Addiction - Drug Profile 72
Enzyme for Cocaine Addiction - Drug Profile 73
EORA-101 - Drug Profile 74
EP-11313 - Drug Profile 75
FP-004 - Drug Profile 76
Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile 77
h-2E2 - Drug Profile 78
ibudilast - Drug Profile 79
istradefylline - Drug Profile 89
ITI-333 - Drug Profile 92
IXT-m200 - Drug Profile 93
JDTic - Drug Profile 96
JQ-1 - Drug Profile 97
KDAC-0001 - Drug Profile 98
levofacetoperane - Drug Profile 99
lofexidine hydrochloride - Drug Profile 100
MC-100093 - Drug Profile 103
naltrexone hydrochloride SR - Drug Profile 104
NLS-10 - Drug Profile 106
NS-2359 - Drug Profile 107
OMS-405 - Drug Profile 109
OMS-527 - Drug Profile 111
OPNT-001 - Drug Profile 113
OREX-1019 - Drug Profile 114
OREX-1038 - Drug Profile 115
oxycodone hydrochloride - Drug Profile 116
RBP-8000 - Drug Profile 118
Recombinant Enzyme for Cocaine Abuse - Drug Profile 120
RO-5256390 - Drug Profile 121
SERx-480 - Drug Profile 122
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 123
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 124
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 125
Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 126
Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile 127
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 128
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130
Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 131
Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 132
Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile 133
Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile 134
Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile 135
Vaccine for Cocaine Addiction - Drug Profile 136
Vaccine for Drug Abuse - Drug Profile 137
Vaccine for Methamphetamine Abuse - Drug Profile 138
Vaccine for Methamphetamine Addiction - Drug Profile 139
VU-0463841 - Drug Profile 140
Drug Addiction - Dormant Projects 141
Drug Addiction - Discontinued Products 144
Drug Addiction - Product Development Milestones 145
Featured News & Press Releases 145
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157

List of Tables

Number of Products under Development for Drug Addiction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017
Drug Addiction - Pipeline by Aelis Farma SAS, H2 2017
Drug Addiction - Pipeline by Aphios Corp, H2 2017
Drug Addiction - Pipeline by BioCorRx Inc, H2 2017
Drug Addiction - Pipeline by Cerecor Inc, H2 2017
Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Drug Addiction - Pipeline by Curemark LLC, H2 2017
Drug Addiction - Pipeline by Egalet Corp, H2 2017
Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2017
Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017
Drug Addiction - Pipeline by Immunovaccine Inc, H2 2017
Drug Addiction - Pipeline by Indivior Plc, H2 2017
Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2017
Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H2 2017
Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Drug Addiction - Pipeline by Omeros Corp, H2 2017
Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017
Drug Addiction - Pipeline by P2D Bioscience, H2 2017
Drug Addiction - Pipeline by Saniona AB, H2 2017
Drug Addiction - Pipeline by Stada Arzneimittel AG, H2 2017
Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Drug Addiction - Dormant Projects, H2 2017
Drug Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Drug Addiction - Dormant Projects, H2 2017 (Contd..2), H2 2017
Drug Addiction - Discontinued Products, H2 2017